Change over period: —
NSE · MEDPLUS
MEDPLUS
-37.1% from the 52-week high · +3.5% above the low
MedPlus Health Services Ltd. engages in the operation of pharmacies. The company is headquartered in Hyderabad, Telangana and currently employs 21,000 full-time employees. The company went IPO on 2021-12-23. The firm is primarily engaged in retail trading of medicines and general items, wholesale cash and carry and pathological laboratory testing services, wholesale trading and manufacturing of pharmaceutical products, fast-moving consumer goods and beauty products. The company operates through two segments: Retail and Diagnostics. The Retail segment is engaged in retail trading of medicines and general items. The Diagnostics segment is engaged in the diagnostic services. The firm operates approximately 3,882 stores in 552 cities distributed across Tamil Nadu, Andhra Pradesh, Telangana, Karnataka, Odisha, West Bengal, and Maharashtra. Its omni-channel platform enables the Company to service its customers through its stores, as well as its online channels. Its subsidiaries include Optival Health Solutions Private Limited, MHS Pharmaceuticals Private Limited, Kalyani Meditimes Private Limited, and others.
The short version. MEDPLUS reported revenue of ₹2,037 crore for Sep 2026, up 21.3% from a year earlier. Net profit was ₹56 crore (up 0.0% year on year). Return on equity was 11.1% in Mar 2026. Promoter holding was 40.2% in Sep 2026, down 0.19 points over 8 quarters.
1 · The price
How has the stock traded?
MEDPLUS trades 37.1% below its 52-week high and 3.5% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹2,037 cr.
Sep 2026 net profit of ₹56 cr.
0.5 pts lower than a year earlier.
Revenue compounded at 14.8% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2037 | 1880 | 1864 | 1806 | 1679 | 1543 | 1510 | 1561 |
| Net profit | 56 | 33 | 64 | 58 | 56 | 42 | 51 | 46 |
| Net margin % | 2.8 | 1.8 | 3.4 | 3.2 | 3.3 | 2.7 | 3.4 | 2.9 |
| EPS (₹) | 4.67 | 2.76 | 5.33 | 4.82 | 4.63 | 3.54 | 4.29 | 3.84 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | 6892 | 6136 | 5625 | 4558 | 3779 |
| Net profit | 220 | 150 | 65 | 50 | 96 |
| Net margin % | 3.2 | 2.4 | 1.2 | 1.1 | 2.5 |
| EPS (₹) | 18.3 | 12.56 | 5.48 | 4.17 | 8.03 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 11.1% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 11.1 | 8.6 | 4.2 | 3.3 |
| Return on capital % | 12.2 | 10.3 | 6.9 | 5.6 |
| EBITDA margin % | 9.8 | 8.7 | 7.0 | 6.8 |
| Net margin % | 3.1 | 2.4 | 1.2 | 1.1 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 14.8% | — |
| Profit CAGR | 64.0% | — |
4 · The owners
Who holds it, and are they adding?
Down 0.19 pts over 8 quarters.
Down 2.65 pts over 8 quarters.
Up 6.24 pts over 8 quarters.
+8 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 40.39 | 40.34 | 40.32 | 40.29 | 40.29 | 40.22 | 40.19 | 40.2 | -0.19 |
| FII | 15.23 | 15.61 | 16.42 | 16.54 | 16.83 | 15.53 | 14.38 | 12.58 | -2.65 |
| DII | 25.65 | 26.19 | 26.04 | 26.52 | 26.57 | 27.82 | 29.95 | 31.89 | +6.24 |
| Public | 18.69 | 17.82 | 17.18 | 16.61 | 16.26 | 16.4 | 15.44 | 15.29 | -3.4 |
Mutual fund holdings · Oct 2026
37 schemes hold this stock
29 the month before.
- ICICI Prudential Contra Fund4.61% of NAV
- ICICI Prudential Healthcare Fund4.3% of NAV
- ICICI Prudential Balanced Hybrid Fund2.3% of NAV
- NIPPON INDIA PHARMA FUND2.26% of NAV
- Nippon India Focused Fund1.53% of NAV
- ICICI Prudential Innovation Fund1.49% of NAV
- Kotak Small Cap Fund1.16% of NAV
- Franklin India Small Cap Fund1.03% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for MEDPLUS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Retailing stocks
Quick answers
Common questions about MEDPLUS
What is the MEDPLUS share price?
MEDPLUS (MEDPLUS) last closed at ₹590.95, down 1.57% on the day. Its 52-week range is ₹579.90 to ₹953.90.
What is the market cap of MEDPLUS?
MEDPLUS has a market capitalisation of about ₹7,215 crore. Its price-to-earnings ratio is 34.1.
How are MEDPLUS's latest results?
MEDPLUS reported revenue of ₹2,037 crore for Sep 2026, up 21.3% from a year earlier. Net profit was ₹56 crore (up 0.0% year on year). Return on equity was 11.1% in Mar 2026. Promoter holding was 40.2% in Sep 2026, down 0.19 points over 8 quarters.
Who owns MEDPLUS?
As of Sep 2026, shareholding was: Promoter 40.2%, FII 12.58%, DII 31.89%, Public 15.29%.
How many mutual funds hold MEDPLUS?
37 mutual fund schemes held MEDPLUS in October 2026. That compares with 29 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.